Intrinsiqq
Biogen Inc. logo

Biogen Inc.

BIIB

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$37.46B
EPS$2.32
P/E109.22
P/FCF18.09
EV/EBITDA32.89
FCF Yield5.5%
Div. Yield–
Net Debt/FCF2.9x
Biogen Inc. intrinsic value
52-Week Range
$164.42$254.87

Profitability & Returns

Revenue (TTM)

$10.30B

▲ +2.2% YoY

Net Income (TTM)

$348M

▼ -20.8% YoY

Op. Margin

4.32%

▼ -4.0pp YoY

ROIC

1.35%

▼ -1.7pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

$2.07B

▼ -24.7% YoY

Op. Cash Flow (TTM)

$2.25B

▼ -23.3% YoY

Net Debt

$6.10B

Cash & Equiv.

$1.30B

5Y CAGR: -6.0%

5Y CAGR: -11.6%

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BIIB

CompareIntrinsic value
NBIXNeurocrine Biosciences Inc.
$167.40-1.18%85
EXELExelixis Inc.
$69.00-1.20%97
MRNAModerna, Inc.
$223.37-3.45%13
HALOHalozyme Therapeutics Inc.
$100.27-0.40%68
TECHBio-Techne Corporation
$72.80-0.05%41
GILDGilead Sciences Inc.
$168.08+0.08%48
AMGNAmgen Inc.
$465.67-0.30%52
BHCBausch Health Companies Inc.
$8.35+1.21%56

Held by ETFs

BIIB is in 307 US ETFs. The largest of them, with BIIB's weight in each:

Biogen (BIIB) in four numbers

Fair value (earnings)
$18.87
Price $253.40 is 1243% above it.
Intrinsic Value
Quality score
39/100
Best check: cash flow growth, 16.0%. Weakest: return on capital, 1.4%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
109.22
Price to free cash flow 18.09.
Financials

Questions about Biogen

Is Biogen (BIIB) overvalued?

At $253.40, Biogen's price is 1243% above the $18.87 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 109.22 times earnings and 18.09 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Biogen's fair value?

Intrinsiqq's calculator puts Biogen's fair value at $18.87 a share. It grows earnings per share 0% a year for 5 years, applies an exit P/E of 13.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $14.15. Every input can be changed on the Intrinsic Value tab.

Is Biogen a high-quality business?

Biogen scores 39 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 8 checks computed from SEC filings. Its best check is cash flow growth at 16.0%, and its weakest is return on capital at 1.4%. The Quality tab shows every check against its target.

Does Biogen (BIIB) pay a dividend?

No. Biogen (BIIB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 26 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 13 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in BIIB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing BIIB

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.